Families

Read More

HFA News & Notes

Recall of Crickit® Convenience Kits

Click here for FDA recall North American Rescue, LLC Announces A Follow-Up to the Recall of Crickit® Convenience [...] Read More >>

WFH appoints John Bournas as new CEO/ ED

Click for link to WFH Montreal, Canada, January 10, 2012 — The World Federation of Hemophilia is pleased to [...] Read More >>

U.S. Department of Health and Human Services releases Essential Health Benefits Bulletin

On Monday, Dec. 16, the U.S. Department of Health and Human Services (HHS) released a bulletin outlining guidance [...] Read More >>

Contact Info

Hemophilia Federation of America
210 7th St. SE, Suite 200B
Washington D.C., 20003
800.230.9797
202.675.6984
202.675.6983

© 2011 Hemophilia Federation of America · Board of Directors Only · BB Admin Only · Privacy & Legal

Real-World Experience Confirms Low Inhibitor Rate Established in ADVATE Controlled Clinical Studies for Hemophilia Patients

Buenos Aires, Argentina, (July 13, 2010) – Baxter International Inc. (NYSE: BAX) today announced final E.U./U.S. post-authorization safety surveillance (PASS) data that support the safety and efficacy profile of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] previously documented in prospective clinical trials in a new study published in the journal Hemophilia. see more…advate_pass